Novel Therapies Targeting Kidney Disease

Pareto Securities' 15th Annual Healthcare Conference

September 19, 2024




GUARD THERAPEUTICS – IN SHORT

- Recently started Phase 2b POINTER study with candidate drug RMC-035 results expected year-end 2025
 - Granted **FDA Fast Track Designation** (kidney protection in open-heart surgery)
 - Eligible for Breakthrough Designation Therapy
- Clinical PoC established on hard kidney endpoints in placebo-controlled Phase 2a study including 177 patients
- Lead indication >USD 1 bn opportunity first-to-market potential & no approved therapies
- Massive opportunity & unique positioning in kidney disease with preclinical GTX peptide
 - Clinically validated target, robust efficacy in numerous disease models
- Listed on Nasdaq First North Growth Market in Stockholm [GUARD]

VISION

Be a globally recognized leader in nephrology, **pioneering** transformative therapies for kidney disease, and **eliminating** the need for dialysis or kidney transplantation

CHRONIC KIDNEY DISEASE (CKD) – AN INCREASING GLOBAL HEALTH BURDEN REDUCING LIFE SPAN



Modelling of Global Burden of Disease reveals an **increase in predicted deaths due to CKD between 1990 and 2040** (deaths per 100,000) Years of life lost (YLL) due to CKD are predicted to **continue to increase and surpass diabetes** as a cause of YLL by 2040


END-STAGE RENAL DISEASE (ESRD) – A DEVASTATING CONDITION WITH POOR OUTCOMES & SOARING HEALTHCARE COSTS

- Requires life-long dialysis treatment (or kidney transplantation)
- Annual mortality unacceptably high (15-20%)
 - Prognosis worse than many types of metastatic cancer
- High morbidity, poor quality of life
- Cost of patient management very high
 - Medicaid annual spend on ESRD treatment >USD 50 bn
 - ~7% of total Medicaid budget, although ESRD beneficiaries only account for ~1% of Medicaid population



5

GUARD THERAPEUTICS PIPELINE



Therapeutic approach:

"Leverage endogenous A1M defense system"

SYNERGY #1 – A1M TARGET HAS BROAD UTILITY IN KIDNEY DISEASE WITH PROVEN CLINICAL EFFICACY


Evolutionary conserved mechanism – aligned with acute & chronic kidney disease mechanisms

Robust efficacy in numerous preclinical disease models – provides translational confidence

Preferential biodistribution to the kidneys


- relevant exposure in target organ

Clinically validated mechanism in Phase 2 study (n=177) – established proof-of-concept for kidney protection in heart surgery



3-D structure of A1M

SYNERGY #2 – PIPELINE TARGETS BOTH ACUTE & CHRONIC KIDNEY DISEASE TO REDUCE RISK OF ESRD



CKD, chronic kidney disease; ESRD, end-stage renal disease

Clinical results & late phase program



PHASE 2 CLINICAL RESULTS DEMONSTRATE KIDNEY PROTECTION WITH RMC-035 IN HEART SURGERY



- Double-blind placebo-controlled Phase 2a study (AKITA) in open-heart surgery
 - N=177 patients at increased risk for kidney injury (1:1 randomization drug:placebo)

Key results:

- Statistically significant & clinically meaningful improvement of kidney function (Day 90)
 - 4.3 mL/min/1.73m² (full population)
 - 7.9 mL/min/1.73m² (pre-defined subgroup of patients with CKD)
- Reduced proportion of patients with severe loss of kidney function
 - 59% relative risk reduction for composite endpoint MAKE (death, dialysis, ≥ 25% eGFR loss)
 - MAKE is the anticipated primary endpoint in Phase 3

Results support progression to late phase development

Study ROS-05 Clinical Study Report; Thielmann et al., eClinical Medicine 2024 eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; MAKE, major adverse kidney events

PHASE 2b (POINTER) – RESULTS EXPECTED YEAR-END 2025


- Global study (US IND study), recruitment in Europe & Canada
- Sample size ~160 patients
 - 30% required to have CKD
- Two dose arms (60 & 30 mg) & Placebo (2:2:3 randomization)
- Data Monitoring Committee will review safety based on data from 1/3 & 2/3 of patients
- All regulatory & ethics approvals obtained
- First patient enrolled in Q3 2024
- Expected recruitment time ~1 year, 3 months follow-up





OVERVIEW OF PHASE 2b POINTER STUDY





Rx = randomization **EOT =** end-of-treatment **EOS =** end-of-study

- study visit
- administration of study drug
- cardiac surgery
- primary endpoint evaluation

Key endpoints:

<u>Primary:</u> change of renal function (eGFR) from baseline to Day 90

Secondary: MAKE90

CLEAR PATH FOR RMC-035 TOWARDS MARKET APPROVAL

- Fast Track Designation granted by the US FDA
 - Indication eligible for Breakthrough Therapy Designation
- Phase 2b POINTER results expected year-end 2025
- Single pivotal Phase 3 study sufficient to support market approval
 - Primary endpoint is MAKE at Day 90 after surgery (~600 patients)
 - Potential for accelerated approval based on interim analysis of eGFR (~300 patients)

GTX peptides




GTX PEPTIDES – OPPORTUNITY IN LATE-STAGE CKD

- GTX peptides enable subcutaneous delivery & chronic treatment
- Opportunity to improve patient outcomes regardless of underlying CKD etiology
 - Efficacy shown in >10 disease models, supporting therapeutic concept
- Late-stage CKD is an underserved patient group
 - Highest risk for progression to ESRD
 - Often excluded from participation in clinical trials
 - Available CKD therapies frequently discontinued or contraindicated in this patient group
 - Not in scope for novel & specific disease-modifying therapies

Preventing ESRD in patients with late-stage CKD offers strong value proposition for patients, physicians & payors

GTX PEPTIDES IN LATE-STAGE CKD OFFER A UNIQUE COMMERCIAL POSITIONING & STRONG VALUE PROPOSITION

Therapy



CKD, chronic kidney disease; ESRD, end-stage renal disease; CKD classification based on Kidney Disease Improving Global Outcomes

RECENT PHARMA DEALS SPOTLIGHT NEPHROLOGY AS HIGH-GROWTH THERAPEUTIC AREA

Vertex Pharmaceuticals Acquisition of Alpine Immune Sciences (2024)

Deal value **\$4.9 billion**, driven by mid-stage drug candidate povetacicept targeting IgAN. Largest acquisition in biopharma 2024.

Biogen Acquisition of Human Immunology Biosciences (2024)

Deal value \$1.15 billion, single asset (feltzartamab), Phase 2 data in IgAN, primary membranous nephropathy & antibody-mediated rejection

Asahi Kasei Acquisition of Calliditas (2024)

Deal value \$1.1 billion, lead asset Tarpeyo (budesonide) for the treatment of IgAN.

Novartis' Acquisition of Chinook Therapeutics (2023)

Deal value **\$3.5 billion**. This deal was primarily motivated by Chinook's strong pipeline in kidney disease, especially its two late-stage assets, atrasentan and zigakibart, both of which are being developed to treat IgAN.

AstraZeneca Acquisition of CinCor Pharma (2022)

Deal value **\$1.8 billion**. Deal included baxdrostat, an aldosterone synthase inhibitor, for the treatment of uncontrolled hypertension and cardio-renal syndrome.

CSL's Acquisition of Vifor Phama (2021)

Deal value \$12.3 billion, largely driven by product portfolio in the nephrology space.


Vifor Pharma Acquisition of Sanifit Therapeutics (2021)

Deal value **\$205 million** upfront, with potential milestone payments. Lead asset focused on treatment for calciphylaxis, a rare and serious condition associated with CKD. This acquisition expanded Vifor's portfolio in nephrology.

NovoNordisk Acquisition of Corvidia Therapeutics (2020)

Deal value **\$2.1 billion**, goal to strengthen its cardiovascular & renal disease pipeline. Corvidia was developing therapies for CKD patients, including ziltivekimab, a drug for CKD patients with cardiovascular risk.

KEY MILESTONES & DELIVERY ACCORDING TO PLAN



Q & A



SOLID IP POSITION

RMC-035

- Composition of matter until 2037
- Approved in all major regions (US, EU, China, Japan)

GTX

- Composition of matter until 2044
 - Currently in PCT phase
- Potential exclusivity beyond 2044 based on Orphan Drug Designation